Johnson & Johnson (JNJ) has to decide how to resolve the potential conflict in selling both Medivir AB (MVIRB)’s and a competitor’s hepatitis C drugs if the Swedish company’s pill is approved, Medivir’s chief executive officer said. Medivir is developing its TMC435 tablet with New Brunswick, New Jersey-based J&J’s Tibotec Pharmaceuticals Ltd. unit. The Huddinge, Sweden-based biotechnology company said last week the experimental treatment will get a faster review from the U.S. Food and Drug Administration. The medicine may go on sale in late 2013, Medivir CEO Ron Long said in an interview yesterday in London.
